Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001866914 | SCV002121799 | likely benign | Noonan syndrome 9 | 2023-03-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004039022 | SCV003552344 | uncertain significance | Cardiovascular phenotype | 2024-03-21 | criteria provided, single submitter | clinical testing | The p.E1225Q variant (also known as c.3673G>C), located in coding exon 23 of the SOS2 gene, results from a G to C substitution at nucleotide position 3673. The glutamic acid at codon 1225 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this alteration remains unclear. |